Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Novel surrogate markers of CNS inflammation in CSF in the diagnosis of autoimmune encephalitis.

Frontiers in neurology·2026
Same author

Integration of Serum Neurofilament Light Chain and Cortical Dysfunction Improves Diagnostic Accuracy in ALS.

Annals of clinical and translational neurology·2026
Same author

Late Presentation of de Novo Proliferative Glomerulonephritis With Monoclonal IgG Deposits in a Renal Allograft: A Rare Case With an Unusual Clinical Course.

Nephrology (Carlton, Vic.)·2026
Same author

Markers of neuroinflammation in the CSF of patients with difficult to treat psychiatric disease.

Frontiers in psychiatry·2026
Same author

Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial.

BMJ open·2026
Same author

Longitudinal evolution of rheumatoid factor-expressing lymphoma precursors in a patient with Sjögren's disease.

Journal of translational autoimmunity·2026

Related Experiment Video

Updated: Jun 9, 2025

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

2.8K

GDF15 research from bench to bedside.

Samuel N Breit1, David A Brown2, Vicky W W Tsai1

  • 1St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales, Sydney, NSW 2052, Australia.

Cancer Cell
|October 25, 2024
PubMed
Summary

Growth Differentiation Factor 15 (GDF15) is implicated in pregnancy sickness and cancer cachexia. A new study shows a GDF15 antibody may effectively treat cancer-related anorexia and cachexia.

More Related Videos

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.8K

Related Experiment Videos

Last Updated: Jun 9, 2025

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

2.8K
In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Maternal-Fetal Medicine

Background:

  • Elevated Growth Differentiation Factor 15 (GDF15) is linked to anorexia/cachexia syndromes and hyperemesis gravidarum.
  • These conditions significantly impact patient health and pregnancy outcomes.
  • Current treatments for these GDF15-mediated conditions are limited.

Purpose of the Study:

  • To evaluate the efficacy of a therapeutic GDF15 monoclonal antibody.
  • To assess the potential of targeting GDF15 for treating anorexia and cachexia.

Main Methods:

  • A phase 2 clinical study was conducted.
  • Participants received a therapeutic GDF15 monoclonal antibody.

Main Results:

  • The study suggests promising results for the GDF15 antibody treatment.
  • Effective treatment for cancer-related anorexia/cachexia may be achievable.

Conclusions:

  • Targeting GDF15 with monoclonal antibodies presents a potential therapeutic strategy.
  • Further research and development are warranted for GDF15-targeted therapies.